Please use this identifier to cite or link to this item:
Title: The role of stereotactic body radiotherapy (SBRT) in the treatment of oligometastatic prostate cancer (PCa)-Initial experiences at Epworth Radiation Oncology (ERO).
Epworth Authors: Bailey, Nola
Bowden, Patrick
Keywords: Epworth Radiation Oncology, Epworth HealthCare, Richmond, Victoria, Australia
Radiotherapy, Targeted
Targeted Radiotherapy
Prostate Cancer
Cancer of the Prostate
Prostate-Specific Antigen
Radiation Oncology
Oncology, Radiation
Radiology, Therapeutic
Therapeutic Radiology
Disease Progression
Stereotactic Body Radiotherapy
Issue Date: Sep-2014
Citation: Journal of Medical Imaging and Radiation Oncology. Conference Publication: (var. pagings). 58 (pp 177), 2014.
Conference Name: 2014 Combined Scientific Meeting: Imaging and Radiation in Personalised Medicine
Conference Location: Melbourne, Victoria, Australia
Abstract: SBRT aims to deliver an ablative dose of radiotherapy to target tissues, minimising dose to adjacent healthy structures. Oligometastasis describes an intermediate disease state involving five or fewer metastases. Local control (LC) rates of 90% for PCa bony and lymph node metastases treated with SBRT are reported in the literature. This study aims to evaluate the effectiveness of SBRT for PCa oligometastases, assessing improvements in LC, reduction of prostate-specific antigen (PSA) and disease progression.
DOI: 10.1111/1754-9485.12222
Type: Conference Paper
Appears in Collections:Cancer Services
Epworth Prostate Centre
Radiation Oncology

Files in This Item:
File Description SizeFormat  
p 177 The role of SBRT in the treatment of oligometastatic PCa.pdf229.62 kBAdobe PDFView/Open

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.